Twenty-four-hour intraocular pressure control with omidenepag isopropyl 0.002% in patients with glaucoma and ocular hypertension

Shiratori N., Nishio Y., Takeda A., Sugimoto S., Takazawa K., Otsuka N., Ishida N., Shii D., Hori K., Nakamoto K.

2021
Clinical Ophthalmology

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Department of Ophthalmology, Nippon Medical School, Tokyo, Japan; Shinanozaka Clinic, Tokyo, Japan; Japan Medical Affairs Group, Santen Pharmaceutical Co. Ltd., Osaka, Japan

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.

View all Glaucoma publications